Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
27 /100
MEDIUM RISK
Score updated Oct 13, 2026

APGE — Apogee Therapeutics, Inc. Dilution Risk Tracker

Track APGE dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track APGE — Get alerts when the score changes →

As of October 13, 2026, Apogee Therapeutics, Inc. (APGE) has a DilutionWatch DilutionScore of 27/100, rated MEDIUM dilution risk. Apogee Therapeutics, Inc. has a market capitalization of $10.18B, 75.34M shares outstanding, 231 institutional holders tracked. Stored dilution-related fields include ATM program capacity of $350.00M.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
46
💰 Cash Runway
0
📊 Float Risk
20
⚠️ Warrant Exposure
15
🔄 Convertible Debt
15

Dilution Forecast

☀️
Clear
No significant dilution signals
model est. 9%
💰 Capital Raise model 18%
• Active ATM program with $350M remaining capacity
🔔 Track APGE — Get forecast alerts →

Market Data

Market Cap$10.18B
Shares Outstanding75.34M
Float57.83M
Cash$971.93M
Debt$8.05M
Short InterestN/A

Source-Backed Evidence Depth

This public preview uses stored DilutionWatch fields and linked SEC/market records only. Missing values are not estimated.

FieldCurrent ValueBasis
DilutionScore27/100DilutionWatch score record
Shares Outstanding75.34MVerified float table or market cache
Public Float57.83MVerified float table or market cache
Market Cap$10.18BMarket data cache
Cash Runway79.8 monthsDilutionWatch score inputs
Shelf CapacityNone in current score inputsSEC-derived dilution fields
ATM Capacity$350.00MSEC-derived dilution fields
Outstanding WarrantsNone in current score inputsSEC-derived dilution fields

Recent source-backed SEC insight records available on this page: 5.

Recent SEC source mix: FORM 4 5.

The page does not infer future share issuance, financing probability, cash needs, management intent, or price impact when source fields are absent.

Institutional Holdings

QoQ: ↑ 27.7% shares (2026Q1 vs prior)
231 institutional holders · 93.05M shares
#1 T. Rowe Price Investment Management, Inc. 10.30M shares
#2 FMR LLC 9.26M shares
#3 Venrock Adviser, LLC 8.49M shares
+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest4.20M
Days to Cover3.5
% of Float7.3%
FINRA data as of Aug 31, 2026

Recent SEC Activity

Form 4 INSIDER TRANSACTION 2026-09-03
Form 4 INSIDER TRANSACTION 2026-09-03
Form 4 INSIDER TRANSACTION 2026-09-03
Form 4 INSIDER TRANSACTION 2026-09-03
Form 4 INSIDER TRANSACTION 2026-09-03
Full SEC filing analysis available with free account →

Recent News

No recent news available for this ticker.

Factual APGE Dilution Snapshot

Apogee Therapeutics, Inc. (APGE) has a DilutionScore of 27/100, rated Medium dilution risk. Score date: October 13, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

DilutionScore History — Last 90 Days

APGE's DilutionScore is currently 27/100 (Medium risk), with 1 score change tracked over 89 days. The score deteriorated from 39/100 (Medium risk).

Period Score Risk Level Duration
Oct 03 – Oct 13, 202627/100MEDIUM11 days
Jul 16 – Oct 02, 202639/100MEDIUM78 days

Score recalculated daily from SEC filings and market data. Sign up free for real-time score change alerts.

Share Dilution History

APGE shares outstanding have increased 12.9% from 54.83M (Mar 2026) to 61.90M (May 2026). Each increase represents potential dilution to existing shareholders.

Date Shares Outstanding Public Float Change
May 27, 202661.90M57.83M▼ 0.02%
May 16, 202661.90M57.84M▲ 0.10%
May 13, 202661.90M57.79M▲ 8.86%
May 10, 202661.85M53.08M▼ 0.04%
May 04, 202661.85M53.10M▲ 0.34%
Apr 24, 202661.11M52.92M▼ 0.02%
Apr 15, 202661.11M52.93M▼ 0.06%
Mar 28, 202661.11M52.96M▲ 2.21%
Mar 05, 202654.83M51.82M▲ 0.67%

Share counts sourced from verified regulatory filings. Increases indicate dilution events.

Track APGE Dilution Risk in Real-Time
DilutionWatch monitors SEC filings 24/7 and alerts you the moment APGE files a shelf registration, ATM offering, warrant notice, or convertible note. Free tier available — no credit card required.
Start Tracking APGE — Free
Email alert within minutes of any SEC filing Daily DilutionScore™ recalculation Score history & trend tracking Tracks 8,000+ tickers simultaneously

Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,490+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for APGE
APGE FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.